**Question:** All are seen in multiple myeloma EXCEPT:

A. anemia
B. hypercalcemia
C. renal insufficiency
D. osteoporosis

**Core Concept:** Multiple myeloma is a plasma cell disorder characterized by the proliferation of malignant plasma cells in the bone marrow. This leads to the production of monoclonal proteins, which can cause various complications.

**Why the Correct Answer is Right:** Osteoporosis is a consequence of multiple myeloma as the malignant plasma cells secrete excessive amounts of parathyroid hormone-related protein (PTHrP), which stimulates osteoclasts to break down bone tissue. This results in decreased bone mass, making the bones fragile and prone to fractures.

**Why Each Wrong Option is Incorrect:**

A. Anemia (low red blood cell count) can occur in multiple myeloma, but it is not a defining feature of this disease. Although it is a common complication, it is not specific to multiple myeloma and can be seen in other conditions as well.

B. Hypercalcemia (high blood calcium levels) is indeed a common complication in multiple myeloma. The elevated parathyroid hormone-related protein (PTHrP) from the malignant plasma cells contributes to this complication.

C. Renal insufficiency (reduced kidney function) can be present in multiple myeloma, but it is not exclusive to this condition. It is a potential complication due to the effects of monoclonal proteins or direct involvement of renal arteries by myeloma cells.

D. Osteoporosis, as explained above, is a consequence of multiple myeloma due to PTHrP secretion.

**Clinical Pearl:** Osteoporosis is a crucial feature to recognize in clinical practice, as it can lead to fractures and increase morbidity in patients with multiple myeloma. It is essential to differentiate this complication from osteoporosis in other conditions like primary hyperparathyroidism, which is characterized by elevated parathyroid hormone (PTH) secretion.

**Correct Answer:** Osteoporosis (D)

---

In summary, while all listed complications can be seen in multiple myeloma, osteoporosis (option D) is unique to multiple myeloma because of the increased secretion of parathyroid hormone-related protein (PTHrP) by the malignant plasma cells. This is different from the other options which can be seen in various other conditions as well. Recognizing these complications is crucial for appropriate management and patient care.